Overview

• The sale of Sanofi’s consumer health arm, Opella, was completed on April 30, 2025, transferring 50% ownership to U.S. private equity firm Clayton, Dubilier & Rice (CD&R).
• Sanofi retains a 48.2% stake in Opella, while French public investment bank Bpifrance holds 1.8% to address concerns over national health sovereignty and employment.
• The €10 billion proceeds from the transaction are being allocated to share buybacks and growth investments, including initiatives in artificial intelligence.
• Doliprane, France’s most-prescribed over-the-counter drug with 300 million boxes dispensed annually, will remain domestically produced under the new ownership structure.
• Union protests over the sale have subsided at Sanofi’s annual shareholder meeting, but strikes continue at the Amilly site over a separate planned sale.